KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Net Margin (2019 - 2025)

Historic Net Margin for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to 57.22%.

  • Royalty Pharma's Net Margin rose 9000.0% to 57.22% in Q4 2025 from the same period last year, while for Dec 2025 it was 55.68%, marking a year-over-year decrease of 31100.0%. This contributed to the annual value of 55.68% for FY2025, which is 31100.0% down from last year.
  • Royalty Pharma's Net Margin amounted to 57.22% in Q4 2025, which was up 9000.0% from 72.91% recorded in Q3 2025.
  • Over the past 5 years, Royalty Pharma's Net Margin peaked at 145.37% during Q2 2021, and registered a low of 107.83% during Q4 2022.
  • Its 5-year average for Net Margin is 50.24%, with a median of 47.38% in 2024.
  • As far as peak fluctuations go, Royalty Pharma's Net Margin plummeted by -1171500bps in 2022, and later soared by 2282100bps in 2023.
  • Over the past 5 years, Royalty Pharma's Net Margin (Quarter) stood at 9.32% in 2021, then tumbled by -1257bps to 107.83% in 2022, then surged by 212bps to 120.39% in 2023, then plummeted by -53bps to 56.32% in 2024, then increased by 2bps to 57.22% in 2025.
  • Its last three reported values are 57.22% in Q4 2025, 72.91% for Q3 2025, and 15.66% during Q2 2025.